Logo

LBRX

LB Pharmaceuticals Inc Common Stock

LBRX

LB Pharmaceuticals Inc Common Stock • NASDAQ
$17.79 ▲ 7.62% (+1.26)
Market Cap $450.07 M
52w High $20.25
52w Low $13.36
Dividend Yield 0%
P/E -24.04
Volume 85.20K
Outstanding Shares 25.30M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.165M ▼ $-3.556M ▲ 0% $-0.14 ▲ $-3.475M ▲
Q3-2024 $0 $16.078M ▼ $-14.181M ▲ 0% $-0.63 ▲ $-14.176M ▲
Q2-2024 $0 $26.58M ▲ $-27.696M ▼ 0% $-7.82 ▼ $-27.051M ▼
Q1-2024 $0 $16.628M $-16.154M 0% $-4.56 $-16.151M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $314.479M ▲ $320.746M ▲ $10.525M ▼ $310.221M ▲
Q2-2025 $14.225M ▼ $19.248M ▼ $123.121M ▼ $-103.873M ▼
Q1-2024 $72.126M $74.26M $124.706M $-50.446M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2024 $-14.181M ▲ $-22.037M ▼ $28.874M ▲ $20K ▲ $0 ▲ $-22.48M ▼
Q2-2024 $-27.696M ▼ $-15.777M ▼ $6.886M ▲ $3K ▼ $-8.888M ▼ $-15.818M ▼
Q1-2024 $-16.154M $-9.573M $-26.064M $38.292M $2.655M $-9.62M

Five-Year Company Overview

Income Statement

Income Statement LB Pharmaceuticals is still a pure development-stage biotech: it has no product sales yet and its expenses are mainly research and corporate overhead. Losses have been small in absolute dollar terms but have widened recently as clinical activity ramps up. The pattern is exactly what you would expect from a single‑asset clinical company moving toward later-stage trials: a narrow cost base, no revenue, and steady operating and net losses that will likely continue until there is a commercial product or a partnership deal.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets, mostly cash, and essentially no physical infrastructure. Equity is negative, which signals that accumulated losses and obligations exceed the book value of assets. Prior debt appears to have been pared back, but the combination of limited assets and negative equity highlights financial fragility and a high dependence on continued access to external funding, whether through equity raises, partnerships, or other financing.

Cash Flow

Cash Flow Cash flow mirrors the income statement: money is flowing out to fund operations and trials, with no offsetting inflows from product sales. Operating cash burn has been modest but persistent, and there is essentially no spending on heavy equipment or facilities. This lean model keeps fixed costs low but also means the company must periodically raise fresh capital to keep its programs moving, especially as it advances into larger and more expensive studies.

Competitive Edge

Competitive Edge LB Pharmaceuticals is a small player in a very crowded antipsychotic market dominated by large, well‑funded pharmaceutical companies. Its edge rests on one asset, LB‑102, which could be the first of its specific drug class available in the United States and appears differentiated by its safety profile and potential benefits on negative and cognitive symptoms of schizophrenia. Patent protection running well into the next decade provides legal insulation if the drug succeeds. However, size, funding, and commercial reach are all disadvantages versus large incumbents, and single‑asset dependence raises concentration risk.

Innovation and R&D

Innovation and R&D Innovation is the core of the story. LB‑102 is a redesigned version of a proven antipsychotic, engineered to penetrate the brain more effectively while aiming to keep or improve on its safety profile. Early‑stage data suggest a favorable balance of efficacy and tolerability, and the company is preparing a pivotal Phase 3 trial. On top of that, management is exploring a long‑acting injectable form, expansion into bipolar depression, and possibly other neuropsychiatric uses. The upside of this R&D focus is meaningful if the data hold up, but everything hinges on future trial results and regulatory decisions, so scientific and execution risk remain high.

Summary

LB Pharmaceuticals is a very early‑stage, high‑risk biotech centered on a single promising drug for schizophrenia and related conditions. Financially, it has no revenue, runs predictable operating losses, holds only a modest cash cushion, and shows negative equity, all of which point to ongoing dependence on outside capital. Strategically, its strength lies in a differentiated, patent‑protected asset with encouraging mid‑stage data and clear avenues for label and formulation expansion. The main uncertainties are typical for this stage: clinical, regulatory, funding, and commercial execution in a market dominated by large global players. This makes LBRX more of a focused development story than a diversified operating business at this point.

NEWS

November 24, 2025 · 8:00 AM UTC

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 12, 2025 · 4:15 PM UTC

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 12, 2025 · 8:00 AM UTC

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

Read more

November 6, 2025 · 4:05 PM UTC

LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

Read more

November 6, 2025 · 8:00 AM UTC

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

Read more